search
immunotherapy
Trends
- 1Immunotherapy startup Adecto shuts down, blaming funding climate▼Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
Immunotherapy startup Adecto is closing down, with the company attributing its collapse to what it calls a risk-averse funding environment. The announcement underscores the continued pressure on early-stage biotech firms as investors pull back from unproven therapeutic platforms, leaving promising research pipelines without the capital needed to advance into clinical development.
- 2Immunotherapy startup Adecto shuts down, blaming funding climate●Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
Adecto, an immunotherapy startup, has closed down and is attributing its collapse to what it calls a risk-averse funding environment. The company's closure adds to a string of biotech shutdowns as investors pull back from early-stage drug development, and it is drawing attention to how difficult conditions have become for clinical-stage startups seeking capital.